

January, 2009

Toronto, Canada

NoAb BioDiscoveries, Inc. announces the launch of its Quantitative Intracerebral Microdialysis service for determining free drug concentrations in different regions of the brain.

In Vivo evaluation of drug penetration into the Central Nervous System (CNS) is vital for characterizing CNS-targeted compounds. Several methods, such as brain homogenate and Cerebrospinal Fluid (CSF) collection have been developed to study drug CNS distribution. However, these methods cannot accurately assess drug localization in the brain. In contrast to the other methods, quantitative intracerebral microdialysis is a direct method for determining the free drug concentration in the extracellular fluid (ECF) of different brain regions over time.

As part of our commitment to offer cutting-edge discovery services, NoAb BioDiscoveries has established a quantitative intracerebral microdialysis system in freely moving rats. In this system, a brain probe is surgically implanted into a specified region of the brain and the femoral vein and artery are catheterized for drug administration, blood sampling and blood replacement. Artificial CSF is perfused by a syringe pump into the probe at a designated flow rate and the dialysate sample is collected at regular time intervals. Plasma is sampled at the midpoint of the dialysate collection interval and analytes in the plasma and dialysate samples are quantified by LC-MS/MS analysis. The results offer a good indication of blood-brain barrier permeability of the drug, as well as distribution to the site of action.

More information about our microdialysis model and other *In Vivo* pharmacokinetics services can be found at: http://www.noabbiodiscoveries.com/html/invivo/invivo_disc.html

NoAb BioDiscoveries is a discovery stage contract research organization, engaged in developing and providing novel tools for accelerating the drug discovery process. NoAb provides a broad suite of *In Vitro* ADME assays and *In Vivo* drug disposition studies in rodents, helping our clients to profile and shape their compounds into the best candidates for further development.

www.noabbiodiscoveries.com

For more information, please contact:

David K.H. Lee, Ph.D.
Chief Scientific Officer
NoAb BioDiscoveries, Inc.
866-729-6622
dkhlee@noabbiodiscoveries.com